Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$13.01 - $27.22 $11.8 Million - $24.8 Million
-910,678 Reduced 74.22%
316,293 $4.46 Million
Q1 2022

May 13, 2022

SELL
$20.94 - $27.5 $3.52 Million - $4.62 Million
-167,868 Reduced 12.03%
1,226,971 $29.7 Million
Q4 2021

Feb 11, 2022

SELL
$16.79 - $27.09 $640,018 - $1.03 Million
-38,119 Reduced 2.66%
1,394,839 $32.6 Million
Q3 2021

Nov 12, 2021

SELL
$15.78 - $24.77 $177,114 - $278,018
-11,224 Reduced 0.78%
1,432,958 $23.8 Million
Q2 2021

Aug 12, 2021

SELL
$19.4 - $27.42 $2.2 Million - $3.12 Million
-113,618 Reduced 7.29%
1,444,182 $35.2 Million
Q1 2021

May 11, 2021

BUY
$25.02 - $54.99 $4.98 Million - $11 Million
199,130 Added 14.66%
1,557,800 $40.2 Million
Q4 2020

Feb 10, 2021

BUY
$41.04 - $56.79 $14.8 Million - $20.5 Million
361,728 Added 36.28%
1,358,670 $72.6 Million
Q3 2020

Nov 12, 2020

SELL
$36.42 - $57.0 $12.1 Million - $18.9 Million
-331,767 Reduced 24.97%
996,942 $41.1 Million
Q2 2020

Aug 12, 2020

BUY
$39.26 - $52.73 $2.53 Million - $3.4 Million
64,541 Added 5.11%
1,328,709 $64.4 Million
Q1 2020

May 12, 2020

SELL
$31.65 - $46.87 $1.25 Million - $1.85 Million
-39,372 Reduced 3.02%
1,264,168 $53.4 Million
Q4 2019

Feb 12, 2020

SELL
$36.21 - $51.4 $8.82 Million - $12.5 Million
-243,665 Reduced 15.75%
1,303,540 $55.8 Million
Q3 2019

Nov 12, 2019

SELL
$22.22 - $44.01 $165,605 - $328,006
-7,453 Reduced 0.48%
1,547,205 $55.7 Million
Q2 2019

Aug 09, 2019

BUY
$23.32 - $28.12 $9.86 Million - $11.9 Million
422,829 Added 37.36%
1,554,658 $41.6 Million
Q1 2019

May 10, 2019

BUY
$16.17 - $27.38 $14.2 Million - $24.1 Million
879,311 Added 348.22%
1,131,829 $30.4 Million
Q4 2018

Feb 12, 2019

BUY
$14.32 - $22.92 $3.62 Million - $5.79 Million
252,518 New
252,518 $4.08 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Artisan Partners Limited Partnership Portfolio

Follow Artisan Partners Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Artisan Partners Limited Partnership with notifications on news.